4.1 Therapeutic indications
Doxorubicin is a cytotoxic medicinal product that is indicated in the following neoplastic conditions:
• Small-cell lung cancer (SCLC)
• Breast cancer
• Recurrent ovarian carcinoma
• Systemic treatment of local advanced or metastasized bladder carcinoma
• Intravesical prophylaxis of recurrences of superficial bladder carcinoma following transurethral resection
• Neoadjuvant and adjuvant therapy of osteosarcoma
• Advanced soft-tissue sarcoma in adults
• Ewing's sarcoma
• Hodgkin's disease
• Non-Hodgkin's lymphoma
• Acute lymphatic leukaemia
• Acute myeloblastic leukaemia
• Advanced multiple myeloma
• Advanced or recurrent endometrial carcinoma
• Wilms' tumour
• Advanced papillary/follicular thyroid cancer
• Anaplastic thyroid cancer
• Advanced neuroblastoma
Doxorubicin is frequently used in combination chemotherapy regimens with other cytostatic medicinal products.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
This is a Phase 3, open label, randomized study designed to compare the safety and efficacy of IMGN853 to that of selected single-agent chemotherapy (Investigator's choice) in women with platinum-resistant FR-alpha positive advanced...
Vulvar cancer accounts for 5% of the female genital tract cancers. Cutaneous metastases from vulvar cancer are extremely rare and for this reason, it can be difficult to reach a diagnosis with a consequent delay in the treatment.
The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.
Medthority will not be held liable for explicit or implicit errors, or missing data.
Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).